CVS Health shares are trading lower after the CMS 2027 Medicare Advantage Part D Release gave the company's Silverscript Insurance contract, a large Medicare PDP contract, a 2.5-star rating. A lower rating could turn people toward competing plans, which can hurt downstream prescription volume at its retail business.